- Home
- IIF vs ALMS Comparison
IIF vs ALMS Comparison
Compare IIF & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIF
- ALMS
- Stock Information
- Founded
- IIF 1993
- ALMS 2021
- Country
- IIF United States
- ALMS United States
- Employees
- IIF N/A
- ALMS N/A
- Industry
- IIF Trusts Except Educational Religious and Charitable
- ALMS
- Sector
- IIF Finance
- ALMS
- Exchange
- IIF Nasdaq
- ALMS NYSE
- Market Cap
- IIF 230.8M
- ALMS 260.6M
- IPO Year
- IIF N/A
- ALMS 2024
- Fundamental
- Price
- IIF $22.94
- ALMS $8.93
- Analyst Decision
- IIF
- ALMS Strong Buy
- Analyst Count
- IIF 0
- ALMS 7
- Target Price
- IIF N/A
- ALMS $28.17
- AVG Volume (30 Days)
- IIF 45.4K
- ALMS 1.4M
- Earning Date
- IIF 01-01-0001
- ALMS 05-15-2025
- Dividend Yield
- IIF 13.94%
- ALMS N/A
- EPS Growth
- IIF N/A
- ALMS N/A
- EPS
- IIF N/A
- ALMS N/A
- Revenue
- IIF N/A
- ALMS N/A
- Revenue This Year
- IIF N/A
- ALMS N/A
- Revenue Next Year
- IIF N/A
- ALMS N/A
- P/E Ratio
- IIF N/A
- ALMS N/A
- Revenue Growth
- IIF N/A
- ALMS N/A
- 52 Week Low
- IIF $18.95
- ALMS $3.18
- 52 Week High
- IIF $24.41
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- IIF 41.16
- ALMS N/A
- Support Level
- IIF $23.81
- ALMS N/A
- Resistance Level
- IIF $24.41
- ALMS N/A
- Average True Range (ATR)
- IIF 0.35
- ALMS 0.00
- MACD
- IIF -0.04
- ALMS 0.00
- Stochastic Oscillator
- IIF 15.42
- ALMS 0.00
About IIF Morgan Stanley India Investment Fund Inc.
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.